[1] A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia

[2] A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

[3] Is monotherapy for febrile neutropenia still a viable alternative?

[4] Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study

[5] Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole

[6] Piperacillin-tazobactam is more effective than ceftriaxone plus gentamicin in febrile neutropenic patients with hematological malignancies: a randomized comparison

[7] What happens after complete withdrawal of therapy in patients with lupus nephritis

[8] HIV and diarrhea in the era of HAART: 1998 New York State hospitalizations

[9] Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori

[10] Reversal of iron deficiency anemia after Helicobacter pylori eradication in patients with asymptomatic gastritis

[11] Telaprevir for previously untreated chronic hepatitis C virus infection

[12] First-line eradication therapy for Helicobacter pylori in primary health care based on antibiotic resistance: results of three eradication regimens

[13] Comparative activities of cefuroxime, amoxicillin-clavulanic acid, ciprofloxacin, enoxacin, and ofloxacin against aerobic and anaerobic bacteria isolated from bite wounds

[14] Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer

[15] Single- versus multiple-dose antimicrobial prophylaxis for major surgery: a systematic review

[16] Hepatic candidiasis: an increasing problem in immunocompromised patients

[17] 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America

[18] Rapid resolution of cellulitis in patients managed with combination antibiotic and anti-inflammatory therapy

[19] Comparison of single and combination antimicrobial agents for prevention of experimental gas gangrene caused by Clostridium perfringens

[20] Longitudinal follow-up of patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis

[21] Early Improvement in Work Productivity Predicts Future Clinical Course in Depressed Outpatients: Findings From the CO-MED Trial

[22] Vedolizumab as induction and maintenance therapy for ulcerative colitis

[23] A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with haematological malignancies

[24] Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group

[25] Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus

[26] Community-acquired bacterial meningitis in adults

[27] Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th-generation cephalosporin + aminoglycosides: comparative study

[28] A comparative double blind study of amoxycillin/clavulanate vs placebo in the prevention of infection after animal bites

[29] Boceprevir for untreated chronic HCV genotype 1 infection

[30] Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa

[31] Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management

[32] A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia

[33] Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone

[34] Zidovudine therapy protects against Salmonella bacteremia recurrence in human immunodeficiency virus-infected patients

[35] Hemophagocytic lymphohistiocytosis syndrome in Dengue hemorrhagic fever

[36] Relapse of erysipelas following treatment with prednisolone or placebo in addition to antibiotics: a 1-year follow-up

[37] Science and pragmatism in the treatment and prevention of neutropenic infection

[38] Application of the IDSA guidelines for the use of antimicrobial agents in neutropenic patients: impact on reducing the use of glycopeptides

[39] Effect of combination antiretroviral therapy upon rectal mucosal HIV RNA burden and mononuclear cell apoptosis

[40] Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients

[41] Use of corticosteroids in treating infectious diseases

[42] Antibiotic and prednisolone therapy of erysipelas: a randomized, double blind, placebo-controlled study

[43] Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients

[44] Clinical trial: comparative effectiveness of cephalexin plus trimethoprim-sulfamethoxazole versus cephalexin alone for treatment of uncomplicated cellulitis: a randomized controlled trial

[45] Secondary hemophagocytic lymphohistiocytosis in children: an analysis of etiology and outcome

[46] Hepatitis C Virus-Infected Patients Receiving Opioid Substitution Therapy Experience Improvement in Patient-Reported Outcomes Following Treatment With Interferon-Free Regimens

[47] High-dosage co-amoxiclav in a single dose versus 7 days of co-trimoxazole as treatment of uncomplicated lower urinary tract infection in women

[48] Regulation by granulocyte-macrophage colony-stimulating factor and/or steroids given in vivo of proinflammatory cytokine and chemokine production by bronchoalveolar macrophages in response to Aspergillus conidia

[49] Emergence of multidrug-resistant Salmonella typhi in rural southern India

[50] Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis

[51] Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials

[52] Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial

[53] A case-control auditory evaluation of patients treated with artemisinin derivatives for multidrug-resistant Plasmodium falciparum malaria

[54] Effects of postmeal exercise on postprandial glucose excursions in people with type 2 diabetes treated with add-on hypoglycemic agents

[55] Nosocomial transmission of Saccharomyces cerevisiae in bone marrow transplant patients

[56] Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: A prospective study

[57] Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions

[58] An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral Regimens

[59] Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis

[60] Real-world effectiveness and predictors of sustained virological response with all-oral therapy in 21,242 hepatitis C genotype-1 patients

[61] Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial

[62] Recurrent neonatal sepsis and progressive white matter injury in a premature newborn culture-positive for group B Streptococcus: A case report

[63] [Treatment of immune thrombocytopenia: a retrospective study of 40 patients]

[64] Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies

[65] Gentamicin and tetracyclines for the treatment of human plague: review of 75 cases in new Mexico, 1985-1999

[66] Chronic hepatitis B

[67] The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

[68] Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial

[69] Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses

[70] Sofosbuvir for previously untreated chronic hepatitis C infection

[71] Understanding real-world adherence in the directly acting antiviral era: A prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada

[72] Lymphatic filariasis and onchocerciasis

[73] Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice

[74] A severe hepatitis flare in an HBV-HCV coinfected patient during combination therapy with alpha-interferon and ribavirin

[75] De-stiffening drug therapy and blood pressure control

[76] De-stiffening drug therapy and blood pressure control

[77] Assessing bleeding rates, related clinical impact and factor utilization in German hemophilia B patients treated with extended half-life rIX-FP compared to prior drug therapy.

[78] Nonclinical evaluation of IQG-607, an anti-tuberculosis candidate with potential use in combination drug therapy

[79] Serum glutamine synthetase activity as biomarker for tuberculosis diagnosis and monitoring anti-tubercular drug therapy success

[80] Analysis of Fractional-Order Deterministic HIV/AIDS Model During Drug Therapy Treatment

[81] Correction to: Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.

[82] Antimicrobial Drug Therapy Problems Among Patients in the Outpatient Department of Ataye Hospital, Northeast Ethiopia

[83] collaborative drug therapy agreement topics in the state of washington: from dispensing pills to managing ills

[84] kinetics of central macular thickness reduction in patients with macular edema after intravitreal drug therapy

[85] treating children with bronchial asthma that is resistant to traditional drug therapy

[86] changes of nitric oxide and peroxynitrite serum levels during drug therapy in patients with obsessive-compulsive disorder

[87] não-adesão à terapêutica medicamentosa do glaucoma noncompliance with drug therapy for glaucoma

[88] performance of cpred/cobs concentration ratios as a metric reflecting adherence to antidepressant drug therapy

[89] Hepatitis B Virus Reactivation in the Setting of Cancer Chemotherapy and Other Immunosuppressive Drug Therapy